Solabegron + oxybutynin

Solabegron + oxybutynin is a combination of two small molecule drugs under investigation for the treatment of overactive bladder. Solabegron is a selective β3 adrenoceptor agonist that works by stimulating β3 adrenergic receptors in the bladder detrusor muscle, leading to relaxation and increased bladder capacity[2]. Oxybutynin is an anticholinergic/antimuscarinic agent that acts as a muscarinic acetylcholine receptor antagonist to block parasympathetic nerve-mediated contractions of the bladder muscle, thereby reducing symptoms such as urinary urgency and frequency[1][6]. The combination aims to provide synergistic relief from overactive bladder symptoms by targeting different pathways involved in bladder control[6].